Researchers have been working to develop approaches to curing Type 1 diabetes by transplanting healthy islet cells into the pancreas. Investigators at Northwestern University have developed a technique to make the immunomodulation effect of immunosuppressive drugs more effective.

One week after expanding the company’s neurodegenerative diseases partnership with Bristol Myers Squibb, Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.

Eli Lilly forged a multi-year collaborative partnership with China-based Regor Therapeutics Group to discover and develop new therapies for metabolic disorders.

The Janssen Pharmaceutical (a Johnson & Johnson company) medicine Invokana (canagliflozin) has a list of safety warnings, including ketoacidosis, a severe complication of diabetes that is potentially life-threatening. According to an investigation conducted by Reuters, J&J knew of the risk of ketoacidosis, but covered it up.

Shares of vTv Therapeutics climbed in trading on December 7 after the company announced plans to restructure and reduce head count by 65 percent in order to ensure funding for a Phase III trial for lead diabetes program TTP399.

BioSpace reviewed some of the more interesting scientific studies recently published, including research into a potential cause of Alzheimer’s disease and how deleting dysfunctional fat cells could alleviate diabetes.

A study by The National Institutes for Quantum Science and Technology in Japan found that a supplement with seven specific amino acids called Amino LP7 appeared to slow brain degeneration and dementia development in mice.

The latest results from SURPASS-4, the longest and largest completed SURPASS trial to date, showed consistent activity in maintaining A1C and weight control in the almost two years the study ran. SURPASS-4 is part of the Phase III trial evaluating tirzepatide as a potential treatment for type 2 diabetes. 

Vertex Pharmaceuticals announced positive Day 90 data from the first patient in the company’s Phase I/II study of VX-880 in type 1 diabetes (T1D). The therapy is a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy.

High Point, North Carolina-based vTv Therapeutics announced positive results from a mechanistic study of TTP399 in type 1 diabetes patients.